Table 1.

Results of mutation detection

	No metastases		Synchronous metastases		Metachronous metastases
	Number	%	Number	%	Number	%
Total patients (n)	96	-	92	-	93	-
All WT	46	47.9	27	29.3	30	32.3
Total KRAS MT	28	29.2	43	46.7	44	47.3
Total KRAS 12 MT	24	25.0	36	39.1	23	24.7
Total KRAS 13 MT	4	4.2	7	7.6	21	22.6
Total BRAF MT	4	4.2	12	13.0	2	2.2
RAS-RAF-MAPK MT	32	33.3	55	59.8	46	49.5
Total PIK3CA MT	13	13.5	20	21.7	15	16.1
Total PTEN MT	15	15.6	14	15.2	17	18.3
PI3K-PTEN-AKT MT	26	27.1	33	35.9	28	30.1
Only KRAS 12 MT	19	19.8	20	21.7	15	16.1
Only KRAS 13 MT	2	2.1	4	4.3	18	19.4
Only BRAF MT	3	3.1	11	12.0	2	2.2
Only PIK3CA MT	7	7.3	5	5.4	7	7.5
Only PTEN MT	10	10.4	5	5.4	7	7.5
Only KRAS + PIK3CA MT	3	3.1	12	13.0	4	4.3
Only KRAS 12 + PIK3CA MT	2	2.1	8	8.7	2	2.2
Only KRAS 13 + PIK3CA MT	1	1.0	2	2.2	2	2.2
Only KRAS + PTEN MT	3	3.1	6	6.5	6	6.5
Only KRAS 12 + PTEN MT	2	2.1	6	6.5	6	6.5
Only KRAS 13 + PTEN MT	1	1.0	0	0.0	0	0.0
KRAS + PIK3CA + PTEN MT	1	1.0	2	2.2	1	1.1
Only BRAF + PIK3CA MT	1	1.0	1	1.1	0	0.0
Only BRAF + PTEN MT	0	0.0	0	0.0	0	0.0
Only PIK3CA + PTEN MT	1	1.0	0	0.0	3	3.2

WT: wild type; MT: mutant type; Total: patients with at least one gene mutation; Only: patients without other gene mutations. RAS-RAF-MAPK MT: patients with any of KRAS or BRAF mutation. PI3K-PTEN-AKT MT: patients with any of PIK3CA or PTEN mutation.